Article Text

Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis
  1. Yi-Ming Chen1,2,3,
  2. Tsai-Ling Liao1,2,
  3. Hsin-Hua Chen1,2,3,
  4. Der-Yuan Chen4,5,6
  1. 1Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
  2. 2Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan
  3. 3Faculty of Medicine, National Yang Ming University, Taichung, Taiwan
  4. 4Department of Medicine, Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan
  5. 5Department of Medical Research, Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan
  6. 6School of Medicine, China Medical University, Taichung, Taiwan
  1. Correspondence to Professor Der-Yuan Chen, Department of Medicine, Rheumatology and Immunology Center, China Medical University Hospital, Taichung 40447, Taiwan; dychen1957{at}

Statistics from

Tuberculosis (TB) remains a major public health issue: an estimated 10.4 million people developed TB disease and 1.4 million died from it in 2015.1 TB risk was 2.28-fold greater in patients with rheumatoid arthritis (RA) compared with controls,2 and even higher in those receiving biologic therapy.3 Guidelines have recommended that latent TB infection (LTBI) screening should be performed and prophylactic therapy be initiated if LTBI exists.4 Consequently, completion of LTBI treatment is essential for TB control in such patients.

The long therapeutic period and hepatotoxicity are barriers to completing 9-month daily isoniazid (9H) treatment,5 the standard LTBI therapy. Recently, implementing 3-month once-weekly isoniazid plus rifapentine (3HP) by directly observed therapy effectively prevented TB and increased treatment adherence.6 However, 3HP regimen has not been assessed for treating LTBI in RA.

Among 188 …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.